Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
25.88
-0.32 (-1.22%)
Nov 18, 2026, 1:11 PM EST - Market open
Vera Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 55.32 | 354.73 | 92.65 | 45.68 | 43.46 | 79.67 |
Short-Term Investments | 328.72 | 359.86 | 548.21 | 115.04 | 71.19 | - |
Cash & Short-Term Investments | 384.04 | 714.59 | 640.85 | 160.72 | 114.65 | 79.67 |
Cash Growth | -22.79% | 11.51% | 298.75% | 40.18% | 43.90% | 48.26% |
Other Receivables | 2.59 | 3.29 | 3.77 | 0.51 | - | - |
Receivables | 14.57 | 3.29 | 3.77 | 0.51 | - | - |
Prepaid Expenses | 28.69 | 8.47 | 5.21 | 8.56 | 10.33 | 2.38 |
Other Current Assets | 6.91 | 2.54 | 1.38 | 2.24 | 0.72 | 0.48 |
Total Current Assets | 441.29 | 728.88 | 651.22 | 172.02 | 125.7 | 82.54 |
Property, Plant & Equipment | - | 3.3 | 4.33 | 3.04 | 5.22 | - |
Long-Term Investments | - | - | - | - | 0.06 | 0.87 |
Other Long-Term Assets | 3.97 | 2.55 | 0.13 | 0.48 | 0.46 | 0.34 |
Total Assets | 465.75 | 734.73 | 655.68 | 175.55 | 131.44 | 83.75 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 20.17 | 21.9 | 7.67 | 11.12 | 11.99 | 1.39 |
Accrued Expenses | 31.08 | 29.64 | 14.47 | 8.75 | 10.96 | 5.93 |
Current Portion of Leases | - | 0.55 | 1.48 | 2.44 | 2.65 | - |
Other Current Liabilities | 4.53 | 1.37 | 1.75 | - | - | 0.38 |
Total Current Liabilities | 55.78 | 53.46 | 25.37 | 22.3 | 25.6 | 7.69 |
Long-Term Debt | 75.43 | 74.84 | 50.69 | 49.88 | 24.81 | 4.92 |
Long-Term Leases | 1.36 | 1.92 | 2.47 | 1.4 | 3.83 | - |
Other Long-Term Liabilities | - | - | - | 0.29 | 0.29 | 1.54 |
Total Liabilities | 132.57 | 130.21 | 78.53 | 73.86 | 54.53 | 14.16 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.07 | 0.07 | 0.06 | 0.04 | 0.03 | 0.02 |
Additional Paid-In Capital | 1,419 | 1,365 | 1,038 | 410.49 | 290.22 | 193.63 |
Retained Earnings | -1,085 | -760.87 | -461.25 | -309.1 | -213.11 | -124.06 |
Comprehensive Income & Other | -0.7 | 0.79 | 0.39 | 0.25 | -0.22 | - |
Total Common Equity | 333.19 | 604.52 | 577.16 | 101.69 | 76.91 | 69.59 |
Shareholders' Equity | 333.19 | 604.52 | 577.16 | 101.69 | 76.91 | 69.59 |
Total Liabilities & Equity | 465.75 | 734.73 | 655.68 | 175.55 | 131.44 | 83.75 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 76.79 | 77.31 | 54.64 | 53.71 | 31.29 | 4.92 |
Net Cash (Debt) | 307.25 | 637.28 | 586.21 | 107.01 | 83.37 | 74.75 |
Net Cash Growth | -26.88% | 8.71% | 447.82% | 28.36% | 11.53% | 39.10% |
Net Cash Per Share | 4.37 | 9.92 | 10.60 | 2.51 | 3.14 | 5.56 |
Filing Date Shares Outstanding | 72.3 | 71.36 | 63.75 | 54.45 | 44.26 | 27.05 |
Total Common Shares Outstanding | 72.29 | 71.27 | 63.56 | 44.45 | 27.8 | 21.28 |
Working Capital | 385.51 | 675.43 | 625.85 | 149.72 | 100.1 | 74.85 |
Book Value Per Share | 4.61 | 8.48 | 9.08 | 2.29 | 2.77 | 3.27 |
Tangible Book Value | 312.69 | 604.52 | 577.16 | 101.69 | 76.91 | 69.59 |
Tangible Book Value Per Share | 4.33 | 8.48 | 9.08 | 2.29 | 2.77 | 3.27 |